Literature DB >> 25369623

Diagnosis and management of ADHD in children.

Barbara T Felt1, Bernard Biermann1, Jennifer G Christner2, Param Kochhar1, Richard Van Harrison1.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is the most common behavioral disorder in children, and the prevalence is increasing. Physicians should evaluate for ADHD in children with behavioral concerns (e.g., inattention, hyperactivity, impulsivity, oppositionality) or poor academic progress using validated assessment tools with observers from several settings (home, school, community) and self-observation, if possible. Physicians who inherit a patient with a previous ADHD diagnosis should review the diagnostic process, and current symptoms and treatment needs. Coexisting conditions (e.g., anxiety, learning, mood, or sleep disorders) should be identified and treated. Behavioral treatments are recommended for preschool-aged children and may be helpful at older ages. Effective behavioral therapies include parent training, classroom management, and peer interventions. Medications are recommended as first-line therapy for older children. Psychostimulants, such as methylphenidate and dextroamphetamine, are most effective for the treatment of core ADHD symptoms and have generally acceptable adverse effect profiles. There are fewer supporting studies for atomoxetine, guanfacine, and clonidine, and they are less effective than the psychostimulants. Height, weight, heart rate, blood pressure, symptoms, mood, and treatment adherence should be recorded at follow-up visits.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25369623

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  17 in total

Review 1. 

Authors:  David Jerome; Laurence Jerome
Journal:  Can Fam Physician       Date:  2020-10       Impact factor: 3.275

Review 2.  Approach to diagnosis and management of childhood attention deficit hyperactivity disorder.

Authors:  David Jerome; Laurence Jerome
Journal:  Can Fam Physician       Date:  2020-10       Impact factor: 3.275

3.  Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update.

Authors:  Hannah W Haddad; Paul B Hankey; Jimin Ko; Zahaan Eswani; Pravjit Bhatti; Amber N Edinoff; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-07-28

4.  National Norms for the Vanderbilt ADHD Diagnostic Parent Rating Scale in Children.

Authors:  Nathan P Anderson; Jamie A Feldman; David J Kolko; Paul A Pilkonis; Oliver Lindhiem
Journal:  J Pediatr Psychol       Date:  2022-06-07

Review 5.  Diagnosis and Treatment Options for Preschoolers with Attention-Deficit/Hyperactivity Disorder.

Authors:  Sharon Wigal; Phillip Chappell; Donna Palumbo; Shannon Lubaczewski; Sara Ramaker; Richat Abbas
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-01-20       Impact factor: 2.576

Review 6.  Lifetime evolution of ADHD treatment.

Authors:  Federico Mucci; Barbara Carpita; Giovanni Pagni; Alessandra Della Vecchia; Sarah Bjedov; Andrea Pozza; Donatella Marazziti
Journal:  J Neural Transm (Vienna)       Date:  2021-05-15       Impact factor: 3.850

Review 7.  A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.

Authors:  David B Clemow; Chris Bushe; Michele Mancini; Michael H Ossipov; Himanshu Upadhyaya
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-03       Impact factor: 2.570

8.  Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Hironobu Ichikawa; Tasuku Miyajima; Yushiro Yamashita; Masakazu Fujiwara; Akimasa Fukushi; Kazuhiko Saito
Journal:  Neuropsychopharmacol Rep       Date:  2019-12-08

9.  Understanding ADHD: Toward an Innovative Therapeutic Intervention.

Authors:  Allyson Camp; Amanda Pastrano; Valeria Gomez; Kathleen Stephenson; William Delatte; Brianna Perez; Hunter Syas; Anthony Guiseppi-Elie
Journal:  Bioengineering (Basel)       Date:  2021-05-01

10.  A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

Authors:  Ann Childress; Jeffrey Newcorn; Jeffrey G Stark; Russ McMahen; Mark Tengler; Carolyn Sikes
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-05-26       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.